Century Therapeutics (NASDAQ:IPSC) Rating Lowered to Sell at Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Several other brokerages have also recently weighed in on IPSC. Zacks Research upgraded Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Piper Sandler boosted their price objective on shares of Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Leerink Partners cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Century Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $3.80.

Century Therapeutics Price Performance

NASDAQ:IPSC opened at $1.84 on Friday. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.71. The stock’s fifty day moving average price is $1.26 and its two-hundred day moving average price is $0.79. The company has a market cap of $160.82 million, a P/E ratio of -5.75 and a beta of 1.74.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. On average, analysts expect that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Chad Cowan purchased 58,060 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were purchased at an average price of $0.85 per share, with a total value of $49,351.00. Following the acquisition, the insider directly owned 1,045,087 shares of the company’s stock, valued at approximately $888,323.95. This represents a 5.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brent Pfeiffenberger acquired 52,000 shares of the stock in a transaction dated Friday, December 12th. The shares were bought at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the transaction, the chief executive officer owned 3,322,990 shares in the company, valued at approximately $1,927,334.20. This represents a 1.59% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 145,060 shares of company stock worth $97,011 and sold 65,695 shares worth $29,625. 4.37% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds have recently added to or reduced their stakes in IPSC. Two Sigma Investments LP lifted its position in Century Therapeutics by 59.2% in the 3rd quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock worth $454,000 after buying an additional 338,902 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Century Therapeutics by 483.1% during the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock worth $118,000 after acquiring an additional 195,573 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Century Therapeutics in the 2nd quarter worth approximately $248,000. Marshall Wace LLP purchased a new stake in shares of Century Therapeutics in the 2nd quarter valued at $78,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.